Skip to main content

Market Overview

Moderna Analyst Positive On Coronavirus Vaccine Progress, Downgrades Shares On Valuation

Share:
Moderna Analyst Positive On Coronavirus Vaccine Progress, Downgrades Shares On Valuation

Moderna Inc (NASDAQ: MRNA) has been one of the best performing stocks of 2020 thanks to its COVID-19 vaccine development program.

A Needham analyst stepped to the sidelines Wednesday due to the heady valuation.

The Moderna Analyst: Alan Carr downgraded Moderna shares from Buy to Hold and removed a $110 price target. 

The Moderna Thesis: Moderna's stock price appreciation reflected the significant progress the biopharma has made in 2020 toward validation of its mRNA platform, particularly through the discovery and development of its COVID-19 vaccine mRNA-1273, Carr said in the downgrade note. 

A favorable vote is likely in the Adcom meeting scheduled for Dec. 17, and emergency use authorization could come soon after, the analyst said.

Needham also expects approvals in all other regions where the vaccine candidate is under review. 

Moderna is likely to produce and sell 500 million doses of mRNA-1273 in 2021, Carr said.

An emergency use authorization issuance could prop up the stock, although the nod is unlikely to justify a meaningfully higher price target, the analyst said. 

Further upside is likely if Moderna is able to source raw material for production of 1 billion total doses in 2021 and competitors — including AstraZeneca plc (NASDAQ: AZN), Johnson & Johnson (NYSE: JNJ), Novavax, Inc. (NASDAQ: NVAX) and Sanofi SA (NASDAQ: SNY) — generate disappointing effectiveness data, according to Needham. 

MRNA Price Action: At last check, Moderna shares were slipping 7.29% to $157.53, having gained 770% year-to-date.

Related Link: Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates

Latest Ratings for MRNA

DateFirmActionFromTo
Mar 2021Chardan CapitalMaintainsBuy
Feb 2021Brookline CapitalMaintainsBuy
Feb 2021Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for MRNA
View the Latest Analyst Ratings

 

Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Downgrades Health Care Analyst Ratings Movers Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com